XML 47 R32.htm IDEA: XBRL DOCUMENT
v3.20.2

Summary of Significant Accounting Policies - Schedule of Percentage of Revenues and Accounts Receivables from Customers (Details) - Customer Concentration Risk | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019
VA MVP | Revenues |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage | 76.00% | 54.00% | 76.00% | 56.00% |
VA MVP | Accounts Receivable |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage |  |  | 17.00% |  | 19.00%
Pfizer Inc. | Revenues |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage | 10.00% | 23.00% |  | 20.00% |
Pfizer Inc. | Accounts Receivable |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage |  |  | 44.00% |  | 23.00%
Customer D | Revenues |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage |  | 12.00% |  |  |
Indivumed GmbH | Accounts Receivable |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage |  |  |  |  | 30.00%
Customer H | Accounts Receivable |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |
Concentration risk percentage |  |  | 14.00% |  |

X
- Definition Summary of significant accounting policies. + References No definition available. + Details
Name: | psnl_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | psnl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=psnl_VeteransAffairsMillionVeteranProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=psnl_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=psnl_CustomerDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=psnl_IndivumedGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=psnl_CustomerHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |